For adult patients with unresectable locally advanced or mTNBC who have received 2 or more prior systemic therapies, at least one of them for metastatic disease, TRODELVY demonstrated

3X LONGER MEDIAN PFS VS SINGLE-AGENT CHEMOTHERAPY

  • Single-agent chemotherapy included eribulin (n=139), capecitabine (n=33), gemcitabine (n=38), and vinorelbine (n=52)

88% of patients in the full population were BM-neg,1 and PFS and OS results were statistically significant across both the BM-neg and full populations 2

Primary endpoint: Kaplan-Meier estimates of median PFS by BICR based on RECIST 1.1 criteria (BM-neg population)2*

Primary endpoint:
Kaplan-Meier estimates
of median PFS by BICR
based on RECIST 1.1 criteria
(BM-neg population)2*

*PFS is defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.

In the full population, TRODELVY demonstrated statistically significant median PFS results vs single-agent chemotherapy1

  • Median PFS was 4.8 months for TRODELVY (95% CI: 4.1–5.8) (n=267) vs 1.7 months with single-agent chemotherapy (95% CI: 1.5–2.5) (n=262); HR: 0.43 (95% CI: 0.35–0.54) P<.0001

Exploratory findings in previously treated, stable BM-positive patients1

  • Median PFS was 2.8 months for TRODELVY (95% CI: 1.5–3.9) vs 1.6 months with single-agent chemotherapy (95% CI: 1.3–2.9); HR: 0.65 (95% CI: 0.35–1.22)

MEDIAN OS OF 1 YEAR WITH TRODELVY

Statistically significant results were demonstrated vs patients treated with single-agent chemotherapy across both the BM-neg and full populations

Secondary endpoint: Kaplan-Meier plot of median OS (BM-neg population)2

Secondary endpoint:
Kaplan-Meier plot of
median OS
(BM-neg population)2

In the full population, TRODELVY demonstrated statistically significant improvement in median OS vs single-agent chemotherapy1

  • Median OS was 11.8 months for TRODELVY (95% CI: 10.5–13.8) (n=267) vs 6.9 months with single-agent chemotherapy (95% CI: 5.9–7.6) (n=262); HR: 0.51 (95% CI: 0.41–0.62) P<.0001

Exploratory findings in previously treated, stable BM-positive patients1

  • Median OS was 6.8 months for TRODELVY (95% CI: 4.7–14.1) vs 7.4 months with single-agent chemotherapy (95% CI: 4.7–11.1); HR: 0.87 (95% CI: 0.47–1.63)


ORR OF TRODELVY VS SINGLE-AGENT CHEMOTHERAPY

Secondary endpoint: Objective Response Rate (ORR)† for TRODELVY vs single-agent chemotherapy (BM-neg population)2

Secondary endpoint:
Objective Response Rate (ORR)
for TRODELVY vs single-agent chemotherapy (BM-neg population)2

Limitation: This secondary endpoint was not powered for statistical analysis and should be considered descriptive only. Therefore, the results require cautious interpretation and could represent chance findings.


Results for ORR in the full population 2

  • 31.1% with TRODELVY (n=267) vs 4.2% with single-agent chemotherapy (n=262), OR: 10.99 (5.66–21.36)
    • CR: 3.7% TRODELVY vs 0.8% single-agent chemotherapy
    • PR: 27.3% TRODELVY vs 3.4% single-agent chemotherapy

BICR=blinded, independent, central review; BM-neg=brain metastases negative; CI=confidence interval; CR=Complete Response; HR=hazard ratio; ITT=intention to treat; mTNBC=metastatic triple-negative breast cancer; OR=odds ratio; OS=Overall Survival; PD-L1=programmed death-ligand 1; PFS=Progression-Free Survival; PR=Partial Response; RECIST=Response Evaluation Criteria in Solid Tumors.

References: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021. 2. Data on file. Gilead Sciences, Inc. 2021.

Indication

TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Important Safety Information

Boxed Warning: Neutropenia And Diarrhea
  • Severe or life-threatening neutropenia may occur. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.
  • Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. Administer atropine, if not contraindicated, for early diarrhea of any severity. At the onset of late diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤Grade 1 and reduce subsequent doses.
CONTRAINDICATIONS
  • Severe hypersensitivity reaction to TRODELVY.
WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 61% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever.

Diarrhea: Diarrhea occurred in 65% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 12% of patients. One patient had intestinal perforation following diarrhea. Neutropenic colitis occurred in 0.5% of patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with TRODELVY. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 37% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medication is recommended. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.

Nausea and Vomiting: Nausea occurred in 66% of all patients treated with TRODELVY and Grade 3 nausea occurred in 4% of these patients. Vomiting occurred in 39% of patients and Grade 3-4 vomiting occurred in 3% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 11% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.

ADVERSE REACTIONS

In the ASCENT study (IMMU-132-05), the most common adverse reactions (incidence ≥25%) were fatigue, neutropenia, diarrhea, nausea, alopecia, anemia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.

UGT1A1 Inducers: Exposure to SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.

Please see full Prescribing Information, including BOXED WARNING.